Global Diabetes Mellitus Treatment Market Growth (Status and Outlook) 2023-2029

Global Diabetes Mellitus Treatment Market Growth (Status and Outlook) 2023-2029

Diabetes mellitus (DM), commonly known as diabetes, is a group of metabolic disorders characterized by high blood sugar levels over a prolonged period.

There are two predominant types of diabetes. Type 1 diabetes patients are typically diagnosed in childhood, and their bodies are not able to produce insulin. Type 1 accounts for less than 10% of diabetes patients, but the smaller population doesn't equate to minimal revenues. Synthetic insulin, the go-to treatment for type 1 diabetes, can also be prescribed to type 2 diabetes patients not responding to other treatments.

Type 2 diabetes is more common and differs from type 1 because the body produces insulin but isn't able to process it correctly. Patients are typically diagnosed over the age of 30, there tends to be a genetic predisposition, and obesity is closely related to this type.

LPI (LP Information)' newest research report, the “Diabetes Mellitus Treatment Industry Forecast” looks at past sales and reviews total world Diabetes Mellitus Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Diabetes Mellitus Treatment sales for 2023 through 2029. With Diabetes Mellitus Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diabetes Mellitus Treatment industry.

This Insight Report provides a comprehensive analysis of the global Diabetes Mellitus Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diabetes Mellitus Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diabetes Mellitus Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetes Mellitus Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetes Mellitus Treatment.

The global Diabetes Mellitus Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Diabetes Mellitus Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Diabetes Mellitus Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Diabetes Mellitus Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Diabetes Mellitus Treatment players cover Novo Nordisk, Sanofi, MannKind, Bristol-Myers Squibb and AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Diabetes Mellitus Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Type 1 Diabetes
Type 2 Diabetes

Segmentation by application
Children
Adults
The Old

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Sanofi
MannKind
Bristol-Myers Squibb
AstraZeneca

Please note: The report will take approximately 2 business days to prepare and deliver.